Evidence map›Paper›PMID 41922086›Full record

ArticleJournal for immunotherapy of cancer2026

Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memory.

Annie Yang, Zhifang Zhang, Anthony K Park, Shyambabu Chaurasiya, Sang-In Kim, Jianming Lu, Yoya Vashi, Jennifer Cillis, Hannah Valencia, Courtney Chen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Annie Yang *Depratment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Zhifang Zhang *Depratment of Surgery, City of Hope National Medical Center, Duarte, California, USA yhwoo@coh.org zhifangzhang04@yahoo.com.
Anthony K ParkCancer Immunotherapeutics Program, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-7692-8874
Shyambabu ChaurasiyaDepratment of Surgery, City of Hope National Medical Center, Duarte, California, USA.ORCID http://orcid.org/0000-0002-9543-5458
Sang-In KimDepratment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Jianming LuDepratment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Yoya VashiDepratment of Surgery, City of Hope National Medical Center, Duarte, California, USA.ORCID http://orcid.org/0000-0003-2262-5477
Jennifer CillisDepratment of Surgery, City of Hope National Medical Center, Duarte, California, USA.ORCID http://orcid.org/0009-0007-8784-7915
Hannah ValenciaDepratment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Courtney ChenDepratment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Supriya DeshpandeDepratment of Surgery, City of Hope National Medical Center, Duarte, California, USA.ORCID http://orcid.org/0009-0009-7294-0126
Yuman FongDepratment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Yanghee WooDepratment of Surgery, City of Hope National Medical Center, Duarte, California, USA yhwoo@coh.org zhifangzhang04@yahoo.com.ORCID http://orcid.org/0000-0002-6676-0593

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeritoneal metastasis (PM) from gastric cancer (GC) is associated with poor prognosis and limited treatment options. We investigated a novel peritoneal-targeted therapy using CF33-human sodium iodide symporter (hNIS), a chimeric orthopoxvirus, combined with anti-PD-L1 immune checkpoint blockade in an immunocompetent mouse model of GCPM.

methodsWe evaluated replication and cytotoxicity of CF33-hNIS in human and murine GC cell lines. We assessed a syngeneic mouse model of PM using the transgenic mouse GC ACKPY3944 cells to test the efficacy of intraperitoneal (IP) CF33-hNIS alone and combined with intravenous or IP anti-PD-L1. Next, we performed flow cytometry and immunohistochemistry to analyze immune cell populations of CD3

resultsCF33-hNIS efficiently infected and killed GC cells. In vivo, IP CF33-hNIS alone significantly prolonged survival and increased infiltration of CD3

conclusionsThese findings support a simplified, high-dose IP treatment strategy to overcome immune resistance in GCPM and provide a strong rationale for future clinical evaluation.

Indexed as

B7-H1 AntigenImmune Checkpoint InhibitorsOncolytic VirotherapyPeritoneal NeoplasmsStomach NeoplasmsSymportersAnimalsCell Line, TumorFemaleHumansImmunologic MemoryMiceNeoplasm Recurrence, LocalSodium-Iodide SymportersB7-H1 AntigenImmune Checkpoint InhibitorsSodium-Iodide SymportersSymportersCombination therapyGastric CancerImmune Checkpoint InhibitorImmunotherapyOncolytic virus

Identifiers

PMID41922086
PMCPMC13052681

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.